RE:Equity Financing upcoming? Just my take on all this but ai would say the only patient that represents a clear cut sign of efficacy is the 53% PR. That's not to say the others don't count, they do, but without that PR they are pretty weak as stand alone signs of efficacy. So to me what counts in terms of timing is when did that 53% patients data emerge. If it came in the last 6 patients and so emerged fair recently then for me that's what opens the flood gates to allow them to do the PR.
What I would ask as a Q is what cycle is the PR patient on.
You might be right about equity financing but it might also be the case that the most important result has happened quite recently.
SPCEO1 wrote: The financing yesterday primarily took care of the convert but if TH-1902 is shown to work in phase 1b, then THTX will need money to do larger phase II trials. They could have shared this info earlier but chose not to - makes me think they were saving it for maximum impact before an equity offering. Just a thought - but they would need to raise additional funds for phase II trials if they do not go the partnership route.